UK markets close in 2 hours 18 minutes

Editas Medicine, Inc. (0IFK.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
33.38-12.22 (-26.80%)
As of 7:02PM GMT. Market open.

Editas Medicine, Inc.

11 Hurley Street
Cambridge, MA 02141
United States
617 401 9000

Full-time employees235

Key executives

NameTitlePayExercisedYear born
Mr. James C. MullenChairman, Pres & CEO100.5kN/A1959
Dr. Feng ZhangCo-Founder & Scientific Advisory Board MemberN/AN/AN/A
Dr. George M. ChurchCo-Founder & Scientific Advisory Board MemberN/AN/A1954
Dr. J. Keith JoungCo-Founder & Scientific Advisory Board MemberN/AN/AN/A
Dr. David R. LiuCo-Founder & Scientific Advisory Board MemberN/AN/AN/A
Ms. Michelle RobertsonCFO, Principal Accounting Officer, Treasurer & Assistant Sec.N/AN/A1967
Mr. Harry R. Gill IIISr. VP of OperationsN/AN/A1961
Mr. Mark J. MullikinSr. Director of Fin. & Investor RelationsN/AN/AN/A
Ms. Charlene SternSr. VP & Chief Legal OfficerN/AN/AN/A
Ms. Clare CarmichaelChief HR OfficerN/AN/A1960
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary genome editing platform based on CRISPR technology, which includes CRISPR/Cas9, CRISPR/Cas12a, and engineered forms of both of these CRISPR systems to target genetically addressable diseases and therapeutic areas. It also develops EDIT-101, which is in Phase 1/2 clinical trial for the treatment of Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. In addition, the company develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 treat sickle cell disease and beta-thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; strategic research collaboration Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease; and research collaboration with Sandhill Therapeutics, Inc. to develop allogeneic healthy donor derived NK cell medicines for the treatment of solid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Editas Medicine, Inc.’s ISS governance QualityScore as of 2 December 2020 is 8. The pillar scores are Audit: 2; Board: 9; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.